Clinical Trial Detail

NCT ID NCT03141034
Title Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Irinotecan + Ramucirumab

Age Groups: adult senior

No variant requirements are available.